GLORIA

GEOMAR Library Ocean Research Information Access

Language
Preferred search index
Number of Hits per Page
Default Sort Criterion
Default Sort Ordering
Size of Search History
Default Email Address
Default Export Format
Default Export Encoding
Facet list arrangement
Maximum number of values per filter
Auto Completion
Topics (search only within journals and journal articles that belong to one or more of the selected topics)
Feed Format
Maximum Number of Items per Feed

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Kamijo, Takehiko  (2)
  • Ohira, Miki  (2)
  • Medicine  (2)
  • 1
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 70, No. 8_Supplement ( 2010-04-15), p. 4964-4964
    Abstract: p53 is one of the major tumor suppressors and promotes apoptotic cell death by transcriptional activation of pro-apoptotic target genes. In malignant human tumors, however, its tumor suppressive activity is frequently inactivated by somatic mutation and/or chromosomal deletion. To enhance the efficacy of chemotherapeutic agents in p53-deficient tumors, it is necessary to elucidate the p53-independent mechanisms of apoptotic cell death. Recently, we have shown that TATA-binding protein-like protein (TLP) transactivates one of p53 family members, TAp63, and induces apoptosis in a p53-independent manner. In response to DNA damage by etoposide, TLP is induced to translocate from cytoplasm to nucleus and enhance promoter activity of TAp63 through direct recruitment onto the promoter. TAp63 stimulated by TLP promotes apoptotic cell death in Hep3B cells null for the p53 alleles. The expression levels of TLP mRNA in human primary non-small lung cancers is low compared with corresponding normal tissues and the downregulation is significantly correlated with low levels of TAp63 and poor outcome of patients’ survival. These results suggest the potential for TLP-TAp63 pro-apoptotic pathway as a therapeutic target for malignant lung cancers. In this study, we analyzed expression of p53 family genes in 106 primary neuroblastomas using quantitative real time RT-PCR, and found that the levels of only TAp63 expression was significantly high in favorable neuroblastomas as compared with unfavorable tumors (p=0.00696) and that its expression was inversely correlated with MYCN expression (p=0.0350). MYCN oncogene is frequently amplified and overexpressed in unfavorable neuroblastoma, and in vitro studies have demonstrated that downregulation of MYCN is the critical steps for neuronal cell death induced by retinoic acids (RA) regardless of p53 status in tumors. However, the precise molecular mechanisms of the down-regulation of MYCN by RA have not been elusive. Intriguingly, TLP and TAp63 are induced in response to RA treatment and TAp63 directly represses MYCN transcription. In addition, RA treatment also inhibits positive auto-regulation of MYCN, leading to further down-regulation of MYCN mRNA levels. Collectively, our results suggest that TAp63 is highly expressed in favorable neuroblastomas and contributes to repression of MYCN by RA treatment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4964.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2010
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: International Journal of Cancer, Wiley, Vol. 123, No. 9 ( 2008-11), p. 2087-2094
    Abstract: Although it has been well documented that loss of human chromosome 11q is frequently observed in primary neuroblastomas, the smallest region of overlap (SRO) has not yet been precisely identified. Previously, we performed array‐comparative genomic hybridization (array‐CGH) analysis for 236 primary neuroblastomas to search for genomic aberrations with high‐resolution. In our study, we have identified the SRO of deletion (10‐Mb or less) at 11q23. Within this region, there exists a TSLC1/IGSF4/CADM1 gene ( Tumor suppressor in lung cancer 1/Immunoglobulin superfamily 4/Cell adhesion molecule 1 ), which has been identified as a putative tumor suppressor gene for lung and some other cancers. Consistent with previous observations, we have found that 35% of primary neuroblastomas harbor loss of heterozygosity (LOH) on TSLC1 locus. In contrast to other cancers, we could not detect the hypermethylation in its promoter region in primary neuroblastomas as well as neuroblastoma‐derived cell lines. The clinicopathological analysis demonstrated that TSLC1 expression levels significantly correlate with stage, Shimada's pathological classification, MYCN amplification status, TrkA expression levels and DNA index in primary neuroblastomas. The immunohistochemical analysis showed that TSLC1 is remarkably reduced in unfavorable neuroblastomas. Furthermore, decreased expression levels of TSLC1 were significantly associated with a poor prognosis in 108 patients with neuroblastoma. Additionally, TSLC1 reduced cell proliferation in human neuroblastoma SH‐SY5Y cells. Collectively, our present findings suggest that TSLC1 acts as a candidate tumor suppressor gene for neuroblastoma. © 2008 Wiley‐Liss, Inc.
    Type of Medium: Online Resource
    ISSN: 0020-7136 , 1097-0215
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2008
    detail.hit.zdb_id: 218257-9
    detail.hit.zdb_id: 1474822-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...